Abstract Emerging data establish dyslipidemia as a significant contributor to the development of diabetic neuropathy. In this review, we discuss how separate metabolic imbalances, including hyperglycemia and hyperlipidemia, converge on mechanisms leading to oxidative stress in dorsal root ganglia (DRG) sensory neurons. We conclude with suggestions for novel therapeutic strategies to prevent or reverse diabetes-induced nerve degeneration.
Significance of the Problem
Diabetes mellitus affects over 20 million people in the United States and a number of diabetic patients are increasing by 5% per year (www.diabetes.org). The most common complication of diabetes is diabetic neuropathy. Depending on the diagnostic criteria used, at least 50% up to 90% of individuals with diabetes will develop diabetic neuropathy. The most common form of diabetic neuropathy is diabetic polyneuropathy, a symmetric loss of nerve function beginning in the toes and progressing in a distal to proximal fashion, yielding what is commonly called a stocking/glove pattern of sensory loss . While all sensory modalities are eventually affected, recent studies show that initially small unmyelinated and thinly myelinated fibers are injured and, especially early in the disease, patients can present with pain. Twenty-five years after the diagnosis of diabetes, the cumulative risk of a lower extremity amputation is 22% and, in the general population, 60% of all lower extremity amputations are secondary to diabetic neuropathy. This represents a cost of over $22 billion per year and a significant loss of quality of life for diabetic patients (Barrett et al., 2007) . Although therapies are available to alleviate the symptoms of diabetic neuropathy, these rarely impact upon the root causes of the disease (Feldman et al., 2002) . The immense physical, psychological, and economic cost of diabetic neuropathy underscores the need for causally targeted therapies (Kles and Vinik, 2006) .
Oxidative Stress in Diabetes
There is a growing consensus, driven by both clinical and basic studies, that oxidative stress underlies the development of the microvascular complications of diabetes, including diabetic neuropathy (Low et al., 1997; Ziegler et al., 2004; Russell et al., 2008; . In type 1 diabetic patients, the severity of microvascular complications parallels the degree of systemic oxidative stress (Sullivan and Feldman, 2005; Giugliano et al., 2008) . With disease and diabetic neuropathy progression, antioxidant potential decreases while lipid peroxidation products increase. Type 2 diabetic patients have a similar oxidative stress profile which directly relates the onset and progression of microvascular complications (Greene et al., 1999; Vincent et al., 2004b) .
In the late 1990s, our group introduced the idea that glucose-mediated oxidative stress injures the peripheral nervous system, leading to eventual death and loss of neurons and supporting Schwann cells (Feldman et al., 1997; Russell et al., 1998; . Investigation of the basic mechanisms underlying this process in DRG neurons identified multiple mechanisms by which hyperglycemia mediates DRG neuron injury. Mitochondrial overload is the principal site of reactive oxygen species (ROS) generation in hyperglycemia (Vincent et al., 2005a) . DRG neurons may be preserved in vitro in the face of hyperglycemic insult by uncoupling agents that relieve the mitochondrial overload (Vincent et al., 2004a) and by lipophilic antioxidants that protect the mitochondria against ROS injury (Vincent et al., 2005a; 2005b) .
Additional cellular mechanisms are activated by hyperglycemia to produce ROS. Hyperglycemia leads to the formation of advanced glycation end products (AGE). DRG neurons express the receptor for AGE and exposure to AGE leads to oxidative stress and injury in DRG neurons that is partially mediated through activation of the nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase complex (Vincent et al., 2007a) . In addition, direct exposure to hyperglycemia leads to the activation of NAD(P)H oxidase (Vincent et al., 2005a) . This complex is formed through recruitment of a combination of a p22-phox subunit and five NOX subunits (Baumer et al., 2008) . Within neurons, NOX2 (or gp91-phox) and p22-phox are expressed within the cell membrane; p47-phox and p67-phox are recruited from the cytoplasm to the membrane when the neuron is exposed to an NAD(P)H oxidase activating stimulus (Murdoch et al., 2006 ). NAD(P)H oxidase activity generates superoxide (O .− 2 ) that promotes mitochondrial dysfunction and apoptosis in the setting of inflammation, neurodegeneration and in atherosclerosis (Stamler, 1996; Silver et al., 2007) . Over time, these mechanisms act in concert with accumulating ROS-induced damage that impairs nerve function and results in the signs and symptoms of diabetic neuropathy (Feldman et al., 1997; Greene et al., 1999; Vincent and Feldman, 2004; Vincent et al., 2004b; 2007b) .
Pathophysiology of Diabetic Neuropathy: More Than Just Glucose
Until recently, we (Feldman et al., 1997; Greene et al., 1999; Vincent et al., 2004b) and other investigators (Low et al., 1997; Brownlee, 2005; Osawa and Kato, 2005; Tomlinson and Gardiner, 2008) in the field contended that hyperglycemia was the driving force underlying the development of diabetic neuropathy. Our opinions were based originally on results from The Diabetes Control and Complications Trial (DCCT). In the DCCT, type 1 diabetic subjects receiving intensive therapy with an average glycosylated hemoglobin (HbA1c) of 7.2% had a reduced 60% cumulative incidence of diabetic neuropathy when compared to patients receiving conventional treatment (average HbA1c of 9.0%) (The Diabetes Control and Complications Trial Research Group, 1993) . However, the continuing longitudinal study of the DCCT, the Epidemiology of Diabetes Complications and Interventions Cohort (EDIC) yielded unanticipated results 20 years later (Genuth, 2006; Martin et al., 2006; Pop-Busui et al., 2009) . Within 1 year of discontinuing the DCCT and beginning EDIC, the glycemic control in the two treatment groups equalized to an average HbA1c of 8% (Genuth, 2006) . All 1,300 patients were examined annually for diabetic neuropathy; one decade later, patients from the intensive-DCCT cohort had a lower incidence of diabetic neuropathy compared to patients from the conventional-DCCT cohort, despite 10 years of convergent glycemic control (Martin et al., 2006) . The underlying mechanism(s) of this result is not determined, but one interesting difference is the lipid profiles of the two groups: a subset of the intensive-DCCT cohort has less dyslipidemia than the conventional cohort (Diabetes Control and Complications Trial Cohort, 1999; Lyons et al., 2004) . This interesting, unanticipated finding is further supported by the Eurodiab Trial, a longitudinal study of over 3,000 individuals with type 1 diabetes (Tesfaye et al., 2005; Tesfaye, 2007) . Of the 1,200 subjects who did not have diabetic neuropathy at baseline, hypertension, serum lipids and body mass index were each independently associated with the risk of developing diabetic neuropathy during a 7-year follow-up period. Of these risk factors, dyslipidemia was closely linked with the onset and progression of diabetic neuropathy [reviewed in (Leiter, 2005) ]. In support of these findings, we recently evaluated the mechanisms underlying diabetic neuropathy progression using indexes of sural nerve morphometry obtained from two identical randomized, placebo-controlled clinical trials (Wiggin et al., 2009 ). Sural nerve myelinated fiber density, nerve conduction velocities, vibration perception thresholds, clinical symptom scores, and a visual analog scale for pain were analyzed in participants with mild-to-moderate diabetic neuropathy. A loss of ≥500 fibers/mm 2 in sural nerve myelinated fiber density over 52 weeks was defined as progressing diabetic neuropathy, and a myelinated fiber density loss of ≤100 fibers/mm 2 during the same time interval as nonprogressing diabetic neuropathy. In this cohort of participants, elevated triglycerides were the only clinical parameter A) The nonprogressing dataset shows no change in MFD (fibers/mm 2 ) over 52 weeks, while the progressing dataset shows a highly significant decrease in MFD. Baseline measurements of triglyceride levels (B) and peroneal motor nerve conduction velocity (C) are significantly different between the progressing and nonprogressing participants. *p < 0.05; **p < 0.01; ***p < 0.0001 (reproduced from Wiggin et al., 2009) .
that correlated with a loss of myelinated fiber density, independent of disease duration, age, diabetes control, or other variables (Wiggin et al., 2009 ). The nerve fiber densities, triglycerides, and motor nerve conduction velocities for the two groups are presented in Fig. 1 .
Dyslipidemia and Neuropathy: An Expanding Problem
The emerging idea that dyslipidemia contributes to the development of diabetic neuropathy may explain the earlier incidence of diabetic neuropathy in individuals with type 2 compared to type 1 diabetes. Lipid profiles are commonly abnormal early in the course of type 2 diabetes in a temporal pattern that correlates with the presence of diabetic neuropathy [Diabetes Atorvastin Lipid Intervention (DALI) Study Group, 2001; Clemens et al., 2004] . In contrast, lipid profiles are nearly always normal in type 1 patients at the time of diabetes diagnosis (Leiter, 2005) . Dyslipidemia develops later in the course of type 1 diabetes, and these abnormal lipid profiles coincide with the delayed onset and progression of diabetic neuropathy (Young et al., 1993; Kempler et al., 2002) . Accumulating data from several large scale trials of patients with type 2 diabetes also point to early dyslipidemia as a major independent risk factor for the development of diabetic neuropathy [reviewed in Leiter, 2005; Gordon and Robinson, 2006) ]. In the United Kingdom Prospective Diabetes Study (UKPDS), 3,867 newly diagnosed type 2 patients were randomized into either intensive treatment with an oral hypoglycemic agent or insulin or conventional treatment with diet. After 10 years, intensive treatment resulted in approximately 1% lower HbA1c vs. conventional treatment but there was no difference in the development of diabetic neuropathy between the two groups, which had similar lipid and blood pressure profiles [UK Prospective Diabetes Study (UKPDS) Group, 1998 ]. This finding, at first unexpected in light of the earlier DCCT data, was supported by the VA Cooperative Study, which demonstrated no difference in the prevalence of diabetic neuropathy in type 2 diabetic patients over a 2-year period comparing standard and intensive glycemic control (Azad et al., 1999) . These results suggested that independent factors other than glycemic control are critical to the development of diabetic neuropathy (Leiter, 2005) .
As with EDIC and Eurodiab, analysis of the UKPDS and VA cooperative data points to dyslipidemia as a critical independent factor for the development of diabetic neuropathy (Leiter, 2005) . Type 2 diabetes clusters with risk factors for coronary heart disease including obesity, hypertension, and dyslipidemia; individuals with two or more of these factors are diagnosed with the metabolic syndrome (Fonseca, 2005; Grundy, 2005; Bonora, 2006; Zimmet and Alberti, 2008) . In a cross-sectional study of 548 type 2 diabetic subjects, those with metabolic syndrome were twice as likely to have diabetic neuropathy (Isomaa et al., 2001) , and the driving factor was dyslipidemia. In a European study of 85 type 2 diabetic patients with at least two additional metabolic syndrome parameters, the prevalence of microvascular complications, including diabetic neuropathy, increased with each additional parameter present (Isomaa et al., 2001) ; abnormalities in (low-density lipoprotein) LDL profiles were more closely related to diabetic neuropathy than hyperglycemia. Finally, prospective studies of patients with idiopathic neuropathy, including our own recently published work, confirm a higher prevalence of hyperlipidemia than impaired glucose tolerance or hypertension, suggesting that dyslipidemia is an essential factor underlying nerve injury (Gordon and Robinson, 2006; Wiggin et al., 2009 ). Collectively, this evolving and exciting literature links dyslipidemia to the development and progression of diabetic neuropathy. Fig. 2 outlines our current understanding of the factors that contribute to the development of diabetic neuropathy.
Lipid Modification in Diabetes
We have now employed cell culture and mouse models of diabetic neuropathy and suggest that oxLDLs are one notable 'lipid factor' responsible for nervous system injury (Vincent et al., 2009) . LDL is the primary carrier of cholesterol (Hammer et al., 1995) and vitamin E (Heinecke, 1987) within the plasma. Systemic oxidative stress results in the modification of these lipoproteins, which is well characterized in atherosclerosis (Willems et al., 1998; Tsuzura et al., 2004) . LDLs spontaneously oxidize in the presence of ROS such as superoxide (O .− 2 ) to form oxLDLs (Hammer et al., 1995) . Cholesterol carrying LDLs is more prone to oxidation than smaller, high-density particles (Krentz, 2003) .
oxLDLs are critically involved in endothelial cell dysfunction, evident from the large body of literature implicating oxLDLs in atherosclerotic lesion formation (Li and Mehta, 2005; Ceriello, 2006; Genuth, 2006) . oxLDL is strongly cytotoxic, which may explain the areas of necrosis detected within atherosclerotic lesions (Tsuzura et al., 2004; Li and Mehta, 2005; Pennathur and Heinecke, 2007; Thum and Borlak, 2008) . In man, oxLDL is a highly analytic marker for macrovascular disease, including stroke and myocardial infarction (Tsimikas et al., 2005) . In patients with types 1 and 2 diabetes, serum levels of oxLDL in proportion to total LDL particles are associated with diabetic neuropathy (Willems et al., 1998; Tsuzura et al., 2004) . Fig. 3 illustrates our findings that oxLDLs increase significantly in mice on a high-fat diet. These oxLDLs can be found in the DRG and the mice develop early signs and symptoms of diabetic neuropathy (Vincent et al., 2009 In a different mouse study using obese db/db mice, we immunostained the dorsal root ganglia for ApoB and MDA-oxidized LDL. We observed colocalization of MDA-LDL in green and ApoB in red (yielding a yellow signal) around the neurons (arrows) (A-C reproduced from Vincent et al., 2009). oxLDLs Mediate Cellular Injury via the Scavenger Receptor, LOX-1 oxLDLs cause apoptotic injury and death in both endothelial cells (Dimmeler et al., 1997) and neurons (Papassotiropoulos et al., 1996; DraczynskaLusiak et al., 1998a; 1998b; Keller et al., 1999; Schroeter et al., 2000) . In endothelial cells, oxLDLs induce multiple events associated with apoptotic injury, including Bid degradation, cytochrome c release, and caspase-3 activation (Vindis et al., 2005) . oxLDLs are associated with increased proapoptotic Bax and decreased levels of the anti-apoptotic type I IGF receptor (IGF-IR) in smooth muscle cells (Higashi et al., 2005) . Both death receptor and mitochondrial pathways are involved in atherosclerotic-plaque associated apoptosis induced by oxLDLs (Napoli, 2003) . In neurons, oxLDLs induce DNA fragmentation characteristic of apoptosis in DRG (Papassotiropoulos et al., 1996; Vincent et al., 2009) , striatal neurons (Draczynska-Lusiak et al., 1998b; Schroeter et al., 2000) , and PC-12 cells (Draczynska-Lusiak et al., 1998a) . In motor neurons, oxLDLs increase ROS and activate a caspase-3-dependent death mechanism (Keller et al., 2000) . Specific effects of oxLDL on mitochondria and mitochondrial-mediated apoptotic events in neurons remain unknown.
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oxLDLs exert effects on cells through two primary cell surface receptors, lectin-like oxidized LDL receptor-1 (LOX-1) on endothelial cells and CD36 on macrophages (Yamashita et al., 2007) . Upon receptor-mediated uptake of oxLDL into LOX-1 on both vascular endothelial cells and dorsal root ganglia neurons will bind oxLDL. Subsequently, the oxLDL may be endocytosed or transcytosed. Receptor binding initiates a signaling pathway leading to the activation of NAD(P)H oxidase and may also alter mitochondrial generation of reactive oxygen species. Glucose independently affects these same cellular targets. endothelial cells, oxLDL is transported through the endothelial cell and extruded into the subendothelial region within tissues (Li and Mehta, 2005) . A schematic showing the expression of LOX-1 and the potential effects of oxLDL binding is shown in Fig. 4 . LOX-1 expression is upregulated by oxLDL, which in turn increases intracellular O .− 2 production (Hu et al., 2003) . Shear stress, tumor necrosis factor-α, and free radicals all increase LOX-1 expression levels (Hu et al., 2003) , while lipid lowering drugs decrease expression (Draude et al., 1999) . Hyperglycemia, AGE, and C-reactive protein also increase LOX-1 expression (Iwashima et al., 2000; Schalkwijk and Stehouwer, 2005; Rudijanto, 2007) . Indeed, glucose stimulates LOX-1 expression in both endothelial cells and macrophages, prevented by antioxidants and inhibitors of MAPK and NF-κB Dandapat et al., 2007) . LOX-1 is upregulated in renal tubules in obese, diabetic rats and its activation leads to inflammation and nephropathy (Ueno et al., 2003; Dominguez et al., 2008; Kelly et al., 2008) . Finally, LOX-1 is also expressed on neurons, and polymorphisms in the LOX-1 gene are associated with neurodegenerative disease in humans (Papassotiropoulos et al., 2005) . We examined LOX-1 expression in DRG neurons, and found basal expression that was further increased by exposure to oxLDL (Vincent et al., 2009) . Selected data are presented in Fig. 5 . Subsequent to LOX-1 activation, the DRG neurons rapidly activated NAD(P)H oxidase, increased superoxide generation, and activated a programmed cell death mechanism. DRG neuron injury in the presence of oxLDL was prevented by a LOX-1 blocking antibody, the NAD(P)H oxidase inhibitor apocyanin, or the antioxidant a-lipoic acid (Vincent et al., 2009) .
These data suggest that, in diabetes, neurons are exposed to both glucose and oxLDL which independently increase ROS, and glucose may sensitize neurons to oxLDL-mediated damage via upregulation of LOX-1. Interestingly, oxLDL decreases native LDL-receptor expression in a LOX-1-dependent manner (Hu et al., 2003) . Given the critical role for native LDL receptors in neuronal functioning, synapse maintenance, and myelination following injury (Herz and Bock, 2002) , oxLDL could also predispose neurons to glucose-mediated injury by decreasing native LDL receptor. These ideas await further exploration.
Lipids and Diabetic Neuropathy
If the idea that dyslipidemia contributes to the development of diabetic neuropathy is true (McManis et al., 1994) , lipid lowering drugs may be beneficial in the treatment of diabetic neuropathy. Fenofibrate is a PPARa agonist that lowers plasma lipids by improving their removal by the liver and improving fatty acid metabolism (Harano et al., 2006; Aasum et al., 2008) . In genetic dyslipidemia in mice, including ApoE knockout, leptin deficient, and LDL receptor knockout mice, fenofibrate improves the lipid profile and increases high-density lipoprotein (Lie et al., 2005; Kooistra et al., 2006; Srivastava et al., 2006) . These lipid improvements correlate with prevention of insulin resistance and atherosclerosis (Calkin et al., 2007; Xie et al., 2007; Aasum et al., 2008) . Interest in this drug treatment has expanded with the demonstration that fenofibrate dramatically improves hyperglycemia, insulin resistance, albuminuria, and glomerular lesions in db/db mice (Park et al., 2006) . The FIELD trial demonstrated that fenofibrate improves signs and progression of retinopathy and nephropathy (FIELD Study, 2007; Keech et al., 2007; Simo and Hernandez, 2007; Davis et al., 2008; Firth, 2008) . The Fremantle Diabetes Study was an observational investigation of 1,237 patients with type 2 diabetes. The data suggest that therapy with a statin or fibrate protects against diabetic peripheral sensory neuropathy, but calls for confirmatory evidence via a randomized clinical trial (Davis et al., 2008) . Fenofibrate may also provide neuroprotection against stroke (Deplanque et al., 2003) . We recently demonstrated the potent ability of fenofibrate to prevent hyperglycemia-induced DRG neuron injury in vitro by decreasing mitochondrial . High glucose and oxLDL cause cell death in dorsal root ganglia (DRG) neurons via NAD(P)H oxidase. Adult DRG neurons were exposed to high glucose (25.7 mM) or increasing concentrations of oxLDL and then cell death was quantitated by caspase 3 activation after 5 h. DRG neurons were additionally pretreated with LOX-1 neutralizing antibody (Anti-LOX-1, 100 mg/ml), apocyanin (Apo, 1 mM), or a-lipoic acid (LA, 100 mM). n = 9, *p < 0.01 compared to untreated control, +p < 0.01 compared to no pretreatment (None). (B) Adult DRG neurons were exposed to 30 mg/ml oxLDL and then immunolabeled for NAD(P)H oxidase subunits p47 or gp91. In (B), adult DRG neurons were exposed to high glucose (25.7 mM) or oxLDL (30 mg/ml) for 1 h or 3 h, then lysed for biochemical assays of NAD(P)H oxidase. *p < 0.01 compared to untreated control, +p < 0.05 compared to untreated control (reproduced from Vincent et al., 2009 . We are following this study with an intervention in type 1 diabetic mice and have demonstrated that 0.1% w/w fenofibrate chow significantly decreases total cholesterol and LDL triglycerides (unpublished data).
Future Directions
We maintain our stand that hyperglycemia is also a key mediator of DRG neuron injury particularly in poorly controlled diabetes. Therefore, compounds that improve glycemic control will assist in the prevention of complications. Metformin, a biguanide compound, improves insulin resistance by reducing gluconeogenesis and enhancing peripheral glucose uptake, promoting reduction of the plasma glucose level (Yoon et al., 2007) . Metformin remains as one of the most used glucose regulating drugs in type 2 diabetes (Saenz et al., 2005) and is used in preclinical trials in mice (Yoon et al., 2007; Algire et al., 2008) . Interestingly, dyslipidemia increases in adolescent type 1 diabetic patients with poor glycemic control, again highlighting the complex interplay between glycemia and dyslipidemia (Shamir et al., 2008) . Taken together, the data indicate that strategic use of NAD(P)H oxidase inhibition, antioxidants, anti-LOX-1 therapy, anti-hyperglycemia, and lipid lowering therapies will prevent diabetic neuropathy. Each of these components has been tested in rodents with positive results Park et al., 2006; Dominguez et al., 2008) . Individually, these strategies have not produced significant results in clinical trials, with the exception of a-lipoic acid (Ziegler et al., 2006) . Current investigations are focusing on metabolic deficits in the axon, particularly at the mitochondria (Figueroa-Romero et al., 2008; Wiggin et al., 2008; Edwards et al., 2009) . Further drug refinement and subcellular targeting may be the key to improved efficacy against neuronal injury. E.L.F., R.P.B.), the American Diabetes Association (A.M.V., E.L.F., R.P.B.), the Animal Models of Diabetes Complications Consortium (NIH UO1 DK076160, E.L.F.), the Program for Neurology Research and Discovery, and the A. Alfred Taubman Medical Institute.
